Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used diabetes and obesity medications but have been associated with gastrointestinal (GI) adverse events. However, real-world evidence on comparative GI adverse reaction profiles is limited. Objectives: This study aimed to evaluate GI adverse events among GLP-1 RA users and compare semaglutide, dulaglutide, liraglutide, and exenatide safety regarding the GI adverse reaction profile. Methods: This retrospective cross-sectional analysis utilized real-world data on 10,328 adults with diabetes/obesity in the National Institutes of Health All of Us cohort. New GLP-1 RA users were identified, and GI adverse events were examined. Logistic regression determined factors associated with GI adverse events. Results: The mean age of the study population was 61.4 ± 12.6 years, 65.7% were female, 51.3% were White, and they had a high comorbidity burden. Abdominal pain (57.6%) was the most common GI adverse event, followed by constipation (30.4%), diarrhea (32.7%), nausea and vomiting (23.4%), GI bleeding (15.9%), gastroparesis (5.1%), and pancreatitis (3.4%). Dulaglutide and liraglutide had higher rates of abdominal pain, constipation, diarrhea, and nausea and vomiting than semaglutide and exenatide. Liraglutide and exenatide had the highest pancreatitis (4.0% and 3.8%, respectively). Compared to semaglutide, dulaglutide and liraglutide had higher odds of abdominal pain, and nausea and vomiting. They also had higher odds of gastroparesis than semaglutide. No significant differences existed in GI bleeding or pancreatitis risks between the GLP-1 RAs. Conclusions: In this real-world cohort, GI adverse events were common with GLP-1 RAs. Differences in GI safety profiles existed between agents, with exenatide appearing safer than other GLP-1 RAs, except for gastroparesis. These findings can inform GLP-1 RA selection considering GI risk factors. Further studies are needed to evaluate the causal relationship and GLP-1 RA safety with concomitant medication use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Yet the dominant physiological driver of discontinuation and non-persistence remains gastrointestinal (GI) intolerance, an intrinsic consequence of GLP-1 receptor activation in the gut and brainstem [23,24].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The “All of Us” Research Program
The All of Us Research Program Investigators (2019) · New England Journal of Medicine · doi:10.1056/nejmsr1809937 · Cited by 2,440
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 4×
“GLP-1 RAs comprise several compounds with varying pharmacokinetic properties, duration of action, and clinical effectiveness [1,2].”
InfluentialGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 2×
“GLP-1 RAs comprise several compounds with varying pharmacokinetic properties, duration of action, and clinical effectiveness [1,2].”
The “All of Us” Research Program
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1912496 · Cited by 843
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560 · cited 2×
“Multivariable logistic regression was used to determine factors associated with gastrointestinal adverse events, adjusting for sociodemographics, comorbidities, and medication type.”
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543 · cited 1×
“Multivariable logistic regression was used to determine factors associated with gastrointestinal adverse events, adjusting for sociodemographics, comorbidities, and medication type.”
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023) · JAMA · doi:10.1001/jama.2023.19574 · Cited by 471 · cited 1×
“Recent research has linked the use of GLP-1 RAs for weight loss to an increased risk of pancreatitis, gastroparesis, and bowel obstruction [14].”
The All of Us Research Program: Data quality, utility, and diversity
Ramirez, A. H., Sulieman, L., Schlueter, D. J., Halvorson, A., Qian, J., Ratsimbazafy, F., Loperena, R., Mayo, K., Basford, M., Deflaux, N., et al. (2022) · Patterns · doi:10.1016/j.patter.2022.100570 · Cited by 352 · cited 2×
“This study followed the Strengthening the Reports of Observational Studies in Epidemiology reporting guideline.”
Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01710-0 · Cited by 297 · cited 1×
“This occurs through directly stimulating POMC/CART neurons and indirectly inhibiting neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons, which can lead to reduced energy intake [3].”
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280 · cited 1×
“They are also used as an adjunct for weight loss in people without diabetes [7].”
Diversity and inclusion for the All of Us research program: A scoping review
Mapes, B. M., Foster, C. S., Kusnoor, S. V., Epelbaum, M. I., AuYoung, M., Jenkins, G., Lopez-Class, M., Richardson-Heron, D., Elmi, A., Surkan, K., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0234962 · Cited by 273
Liu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043789 · Cited by 258 · cited 4×
“However, despite these advantages, GLP-1 RAs have been associated with several gastrointestinal (GI) adverse events, though reported differences between specific agents are conflicting [11–13].”
InfluentialGLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248 · cited 2×
“Some GLP-1 RAs have also been approved and marketed specifically for weight loss based on evidence that they reduce food intake by stimulating insulin and inhibiting glucagon secretion postprandially [4].”
Jensterle, M., Rizzo, M., Haluzík, M., & Janež, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02153-x · Cited by 215 · cited 1×
“GLP-1 RAs have also demonstrated effectiveness for weight management and maintenance of weight loss in the treatment of people with overweight and obesity [4–6].”
Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14551 · Cited by 200
Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13353 · Cited by 157
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145 · cited 2×
“However, despite these advantages, GLP-1 RAs have been associated with several gastrointestinal (GI) adverse events, though reported differences between specific agents are conflicting [11–13].”
Shu, Y., He, X., Wu, P., Liu, Y., Ding, Y., & Zhang, Q. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.996179 · Cited by 145
Michos, E. D., López-Jiménez, F. A., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 102
Horowitz, M., Aroda, V. R., Han, J., Hardy, E., & Rayner, C. K. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12872 · Cited by 79
Qin, W., Yang, J., Deng, C., Ruan, Q., & Duan, K. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15386 · Cited by 72
Progress With the All of Us Research Program
Ramirez, A. H., Gebo, K. A., & Harris, P. A. (2021) · JAMA · doi:10.1001/jama.2021.7702 · Cited by 65
Xie, Z., Hu, J., Gu, H., Li, M., & Chen, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1244432 · Cited by 47
Zhou, Y., Chen, M., Liu, L., & Chen, Z. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s348025 · Cited by 46 · cited 1×
“One study found higher reporting odds of GI adverse events with semaglu-tide versus liraglutide [12], while a systematic review of case reports showed higher rates with liraglutide and exenatide [13].”
Representation of Race and Ethnicity in the Contemporary US Health Cohort All of Us Research Program
Kathiresan, N., Cho, S. M. J., Bhattacharya, R., Truong, B. M. T., Hornsby, W., & Natarajan, P. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.2411 · Cited by 42 · cited 1×
“We identified adult patients with newly diagnosed T2DM or obesity enrolled in the All of Us research program, one of the largest and most diverse biomedical cohorts within the U.S.”
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management
Taha, M. B., Yahya, T., Satish, P., Laird, R., Agatston, A. S., Cainzos-Achirica, M., Patel, K. V., & Nasir, K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01041-7 · Cited by 31 · cited 1×
“Treatment guidelines recommend the use of GLP-1 RAs due to their positive impact on T2DM complication prevention, blood pressure and lipid level improvement, and amelioration of sleep apnea [1,8–10].”
Glucagon-like peptide-1 receptor agonists: the key to healthy weight loss maintenance?
Iepsen, E. W., & Torekov, S. S. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab249 · Cited by 5 · cited 1×
“Treatment guidelines recommend the use of GLP-1 RAs due to their positive impact on T2DM complication prevention, blood pressure and lipid level improvement, and amelioration of sleep apnea [1,8–10].”
Cited by
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
The Impact of GLP-1 Receptor Agonists (GLP-1 RAs) on Mental Health: A Systematic Review
Valenta, S. T., Nicastri, A., Perazza, F., Marcolini, F., Beghelli, V., Atti, A. R., & Petroni, M. L. (2024) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-024-00331-y · Cited by 55
Oprea, A. D., Umpierrez, G. E., Sweitzer, B., & Hepner, D. L. (2024) · Anesthesiology · doi:10.1097/aln.0000000000005204 · Cited by 45
Osei, S. P., Akomaning, E., Florut, T. F., Sodhi, M., Lacy, B. E., Aldhaleei, W. A., & Bhagavathula, A. S. (2024) · Diagnostics · doi:10.3390/diagnostics14242829 · Cited by 38
Self-citationRaubenheimer, J., Myburgh, P. H., & Bhagavathula, A. S. (2024) · BMC Global and Public Health · doi:10.1186/s44263-024-00095-w · Cited by 41
Self-citation
Metadata
- Authors
- Aldhaleei, W. A., Abegaz, T. M., & Bhagavathula, A. S.
- Affiliations
- Mayo Clinic (US)
- Florida Agricultural and Mechanical University (US)
- North Dakota State University (US)
- Corresponding author
- Bhagavathula, Akshaya Srikanth
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2024-02-02
- Volume
- 17
- Issue
- 2
- Pages
- 199
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC10891568
- OpenAlex
- W4391485990
- Cited by
- 80
- References
- 27
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 12
- FWCI
- 26.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- North Dakota State University—RCA Research Support (000365)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- GLP-1 receptor agonists, gastrointestinal adverse effects, semaglutide, dulaglutide, liraglutide, exenatide, abdominal pain, constipation, diarrhea, nausea and vomiting, gastroparesis, pancreatitis, diabetes mellitus, obesity, drug safety comparison
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

